Provided are a method and use of microRNA MiR-2911 in regulating an ebola virus. Particularly provided are a method and use of isolated microRNA MiR-2911 in regulating an ebola virus protein gene.

Plant infusions or extracts and compositions including the same are disclosed. The plant infusions or extracts and compositions including the plant infusions or extracts include ingredients that may comply with the United States Department of Agriculture's (USDA's) National Organic Program (NOP) for products labeled as “organic” or “made with organic” and can be used as mitigating compositions and/or a preservative.

Plant infusions or extracts and compositions including the same are disclosed. The plant infusions or extracts and compositions including the plant infusions or extracts include ingredients that may comply with the United States Department of Agriculture's (USDA's) National Organic Program (NOP) for products labeled as “organic” or “made with organic” and can be used as mitigating compositions and/or a preservative.

A nanoemulsion system for transdermal delivery of a pharmaceutical composition or other active agent across at least an outer layer of skin of a patient includes a first phase, a second phase, and a third phase, and at least one pharmaceutical composition or other active agent. The first phase comprises an oil phase, the second phase comprises an aqueous phase, and the third phase comprises a final phase including a preservation agent. A method of preparing a nanoemulsion system for transdermal delivery of at least one pharmaceutical composition or other active agent across at least an outer layer of skin of a patient includes preparing predetermined amounts of first, second and third phases, heating and combining the first and second phases while stirring, cooling the initial mixture prior to adding the third phase, and cooling the resultant mixture to a final temperature while stirring to form the nanoemulsion system.

A nanoemulsion system for transdermal delivery of a pharmaceutical composition or other active agent across at least an outer layer of skin of a patient includes a first phase, a second phase, and a third phase, and at least one pharmaceutical composition or other active agent. The first phase comprises an oil phase, the second phase comprises an aqueous phase, and the third phase comprises a final phase including a preservation agent. A method of preparing a nanoemulsion system for transdermal delivery of at least one pharmaceutical composition or other active agent across at least an outer layer of skin of a patient includes preparing predetermined amounts of first, second and third phases, heating and combining the first and second phases while stirring, cooling the initial mixture prior to adding the third phase, and cooling the resultant mixture to a final temperature while stirring to form the nanoemulsion system.

A composition of Chinese medical herbs capable of inhibiting COVID-19 virus, use of the same, and method of making the same are provided. The composition of Chinese medical herbs includes Pennisetum alopecuroides, Lophatherum gracile, Salvia miltiorrhiza, Lonicera japonica, Houttuynia cordata and Tangerine Peel and is suitable for making a drug capable of inhibiting COVID-19. The method includes: providing Pennisetum alopecuroides, Lophatherum gracile, Salvia miltiorrhiza, Lonicera japonica, Houttuynia cordata and Tangerine Peel; extracting the Chinese medical herbs with an organic solvent to produce an extract; and removing the organic solvent from the extract to obtain the composition of Chinese medical herbs. The composition of Chinese medical herbs suppresses the activity of COVID-19 virus.

A composition of Chinese medical herbs capable of inhibiting COVID-19 virus, use of the same, and method of making the same are provided. The composition of Chinese medical herbs includes Pennisetum alopecuroides, Lophatherum gracile, Salvia miltiorrhiza, Lonicera japonica, Houttuynia cordata and Tangerine Peel and is suitable for making a drug capable of inhibiting COVID-19. The method includes: providing Pennisetum alopecuroides, Lophatherum gracile, Salvia miltiorrhiza, Lonicera japonica, Houttuynia cordata and Tangerine Peel; extracting the Chinese medical herbs with an organic solvent to produce an extract; and removing the organic solvent from the extract to obtain the composition of Chinese medical herbs. The composition of Chinese medical herbs suppresses the activity of COVID-19 virus.

A composition of Chinese medical herbs capable of inhibiting COVID-19 virus, use of the same, and method of making the same are provided. The composition of Chinese medical herbs includes Pennisetum alopecuroides, Lophatherum gracile, Salvia miltiorrhiza, Lonicera japonica, Houttuynia cordata and Tangerine Peel and is suitable for making a drug capable of inhibiting COVID-19. The method includes: providing Pennisetum alopecuroides, Lophatherum gracile, Salvia miltiorrhiza, Lonicera japonica, Houttuynia cordata and Tangerine Peel; extracting the Chinese medical herbs with an organic solvent to produce an extract; and removing the organic solvent from the extract to obtain the composition of Chinese medical herbs. The composition of Chinese medical herbs suppresses the activity of COVID-19 virus.

A stamina-improving composition, a stamina-improving functional food including same and, more specifically, to a stamina-improving natural tea is provided. A stamina-improving composition including as an active ingredient at least one selected from Orostachys japonicus and Vigna vexillata var tsusimensis Matsumura is provided.

A stamina-improving composition, a stamina-improving functional food including same and, more specifically, to a stamina-improving natural tea is provided. A stamina-improving composition including as an active ingredient at least one selected from Orostachys japonicus and Vigna vexillata var tsusimensis Matsumura is provided.